Literature DB >> 28989096

Exploiting 2A peptides to elicit potent neutralizing antibodies by a multi-subunit herpesvirus glycoprotein complex.

Felix Wussow1, Flavia Chiuppesi2, Zhuo Meng2, Joy Martinez2, Jenny Nguyen2, Peter A Barry3, Don J Diamond4.   

Abstract

Neutralizing antibodies (NAb) interfering with glycoprotein complex-mediated virus entry into host cells are thought to contribute to the protection against herpesvirus infection. However, using herpesvirus glycoprotein complexes as vaccine antigens can be complicated by the necessity of expressing multiple subunits simultaneously to allow efficient complex assembly and formation of conformational NAb epitopes. By using a novel bacterial artificial chromosome (BAC) clone of the clinically deployable Modified Vaccinia Ankara (MVA) vector and exploiting ribosomal skipping mediated by 2A peptides, MVA vectors were generated that expressed self-processing subunits of the human cytomegalovirus (HCMV) pentamer complex (PC) composed of gH, gL, UL128, UL130, and UL131A. These MVA vectors expressed 2A-linked HCMV PC subunits that were efficiently cleaved and transported to the cell surface as protein complexes forming conformational neutralizing epitopes. In addition, vaccination of mice by only two immunizations with these MVA vectors resulted in potent HCMV NAb responses that remained stable over a period of at least six months. This method of eliciting NAb by 2A-linked, self-processing HCMV PC subunits could contribute to develop a HCMV vaccine candidate and may serve as a template to facilitate the development of subunit vaccine strategies against other herpesviruses.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2A peptide; Artificial chromosome; Glycoprotein; Herpesvirus; Neutralizing antibody; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 28989096      PMCID: PMC5682205          DOI: 10.1016/j.jviromet.2017.10.006

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  43 in total

1.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  En passant mutagenesis: a two step markerless red recombination system.

Authors:  B Karsten Tischer; Gregory A Smith; Nikolaus Osterrieder
Journal:  Methods Mol Biol       Date:  2010

3.  Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes.

Authors:  Claudio Ciferri; Sumana Chandramouli; Danilo Donnarumma; Pavel A Nikitin; Michael A Cianfrocco; Rachel Gerrein; Adam L Feire; Susan W Barnett; Anders E Lilja; Rino Rappuoli; Nathalie Norais; Ethan C Settembre; Andrea Carfi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

4.  Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies.

Authors:  Anna Kabanova; Laurent Perez; Daniele Lilleri; Jessica Marcandalli; Gloria Agatic; Simone Becattini; Silvia Preite; Dario Fuschillo; Elena Percivalle; Federica Sallusto; Giuseppe Gerna; Davide Corti; Antonio Lanzavecchia
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-01       Impact factor: 11.205

5.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 6.  New concepts in herpes simplex virus vaccine development: notes from the battlefield.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed
Journal:  Expert Rev Vaccines       Date:  2009-08       Impact factor: 5.217

7.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Authors:  Andrea L Szymczak; Creg J Workman; Yao Wang; Kate M Vignali; Smaroula Dilioglou; Elio F Vanin; Dario A A Vignali
Journal:  Nat Biotechnol       Date:  2004-04-04       Impact factor: 54.908

8.  Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.

Authors:  Yingxia Wen; James Monroe; Christine Linton; Jacob Archer; Clayton W Beard; Susan W Barnett; Giuseppe Palladino; Peter W Mason; Andrea Carfi; Anders E Lilja
Journal:  Vaccine       Date:  2014-05-14       Impact factor: 3.641

Review 9.  Epstein-barr virus vaccines.

Authors:  Jeffrey I Cohen
Journal:  Clin Transl Immunology       Date:  2015-01-23

10.  Comparison of homologous and heterologous prime-boost vaccine approaches using Modified Vaccinia Ankara and soluble protein to induce neutralizing antibodies by the human cytomegalovirus pentamer complex in mice.

Authors:  Flavia Chiuppesi; Felix Wussow; Louise Scharf; Heidi Contreras; Han Gao; Zhuo Meng; Jenny Nguyen; Peter A Barry; Pamela J Bjorkman; Don J Diamond
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

View more
  6 in total

1.  Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.

Authors:  Flavia Chiuppesi; Jenny Nguyen; Felix Wussow; Don J Diamond; Soojin Park; Heidi Contreras; Mindy Kha; Zhuo Meng; Teodora Kaltcheva; Angelina Iniguez; Joy Martinez; Corinna La Rosa
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

Review 2.  A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.

Authors:  Don Jeffrey Diamond; Corinna La Rosa; Flavia Chiuppesi; Heidi Contreras; Sanjeet Dadwal; Felix Wussow; Supriya Bautista; Ryotaro Nakamura; John A Zaia
Journal:  Expert Rev Vaccines       Date:  2018-10-03       Impact factor: 5.217

Review 3.  Neutralization of Human Cytomegalovirus Entry into Fibroblasts and Epithelial Cells.

Authors:  Felix Wussow; Flavia Chiuppesi; Heidi Contreras; Don J Diamond
Journal:  Vaccines (Basel)       Date:  2017-10-31

4.  Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.

Authors:  Flavia Chiuppesi; Marcela d'Alincourt Salazar; Heidi Contreras; Vu Nguyen; Joy Martinez; Soojin Park; Jenny Nguyen; Mindy Kha; Angelina Iniguez; Qiao Zhou; Teodora Kaltcheva; Roman Levytskyy; Nancy Ebelt; Tae Kang; Xiwei Wu; Tom Rogers; Edwin Manuel; Yuriy Shostak; Don Diamond; Felix Wussow
Journal:  Res Sq       Date:  2020-07-17

5.  Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.

Authors:  Flavia Chiuppesi; Marcela d'Alincourt Salazar; Heidi Contreras; Vu H Nguyen; Joy Martinez; Soojin Park; Jenny Nguyen; Mindy Kha; Angelina Iniguez; Qiao Zhou; Teodora Kaltcheva; Roman Levytskyy; Nancy D Ebelt; Tae Hyuk Kang; Xiwei Wu; Thomas Rogers; Edwin R Manuel; Yuriy Shostak; Don J Diamond; Felix Wussow
Journal:  bioRxiv       Date:  2020-07-02

6.  MVA-Vectored Pentameric Complex (PC) and gB Vaccines Improve Pregnancy Outcome after Guinea Pig CMV Challenge, but Only gB Vaccine Reduces Vertical Transmission.

Authors:  Heidi Contreras; Felix Wussow; Claudia Fernández-Alarcón; Craig Bierle; Jenny Nguyen; Don J Diamond; Mark R Schleiss
Journal:  Vaccines (Basel)       Date:  2019-11-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.